CTIS2023-503703-28-00进行中（未招募）1 期
BCLT/22/IBU-BE/001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCERCTIS2023-508058-24-01ovImmune S.A.12
进行中（未招募）
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCEROCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCERCTIS2023-508058-24-00ovImmune S.A.12
进行中（未招募）
1 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.CTIS2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
进行中（未招募）
1 期
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphomaewly diagnosed aggressive B-cell lymphoma (a-BCL)MedDRA version: 20.1Level: LLTClassification code: 10080217Term: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10023699Term: Large B-cell lymphoma subtype primary mediastinal (Thymic) large B-cell lymphoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065863Term: Anaplastic large-cell lymphoma primary cutaneous type Class: 10029104MedDRA version: 23.0Level: PTClassification code: 10071977Term: Anaplastic lymphoma kinase gene mutation Class: 100000004850CTIS2023-506094-35-00Celgene Corp.174
招募中
1 期
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung CancerOncologyMedDRA version: 21.1Level: PTClassification code: 10029517Term: Non-small cell lung cancer stage I Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029516Term: Non-small cell lung cancer stage 0 Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029518Term: Non-small cell lung cancer stage II Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non-small cell lung cancer stage III Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029515Term: Non-small cell lung cancer recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029520Term: Non-small cell lung cancer stage IIIA Class: 100000004864CTIS2023-506539-14-00Systimmune Inc.144